NICE has issued final guidance not recommending crizotinib (Xalkori, Pfizer) for previously treated anaplastic-lymphoma-kinase-positive advanced non-small-cell lung cancer. Commenting on the draft guidance, Sir Andrew Dillon, NICE Chief Executive, said: â€œHaving already recommended a number of treatments for the various stages of non-small-cell lung cancer, we are disappointed not to be able to add crizotinib as a treatment option for patients. However, although the independent committee that considered the evidence found crizotinib to be clinically effective treatment for ALK-positive non-small-cell lung cancer, crizotinib could not be considered a cost-effective use of NHS resources, even when taking into consideration the manufacturer's patient access scheme.” For more details, go to: http://www.nice.org.uk/newsroom/pressreleases/PfizerCrizotinibNotGoodValueNHSMoney.jsp